CHARLOTTESVILLE, Virginia, February 11, 2011 — Biovista announced today that it is presenting at the 5th World Generic Medicines Congress, London UK, on Thursday 24 February 2011. Biovista’s CEO, Dr. Andreas Persidis, will give a presentation on the business and science of repositioning generic medicines at the 5th annual World Generic Medicines Congress Europe of … Read More
News
Biovista announces a Webinar on Drug Safety
CHARLOTTESVILLE, Virginia, February8, 2011 — Biovista announced today that it is co-presenting a webinar with FDA/OCP on Predicting Serious Adverse Events Using Mechanism of Action, on Thursday, 24 February 2011. Biovista’s President, Dr. Aris Persidis, will co-present together with Dr. Darrell Abernathy, Associate Director for Drug Safety in the Office of Clinical Pharmacology at the … Read More
Biovista Inc. to Present at 4th Annual OneMedForum and Biotech Showcase™ in San Francisco
Charlottesville, VA – January 4, 2011 – Biovista Inc., a privately held drug discovery company focused on finding novel uses for existing drugs, announced today that Aris Persidis, Ph.D, president and co-founder of Biovista, will be presenting at the 4th Annual OneMedForum 2011 conference. Dr. Persidis’ presentation will be given at the Sir Francis Drake … Read More
Biovista – a Dedicated Approach to Drug Repositioning
Seeking Alpha’s Jason Chew writes about Biovista’s Drug Repositioning approach: Following up my previous piece on drug repositioning by Orexigen with its diet pill, Contrave, I spoke with Dr. Aris Persidis, President and co-founder of Biovista- a leading company in the drug repositioning business. Drug repositioning is the discovery and development of novel indications for … Read More
Bioworld: Biovista AI boosts Drug Discovery
BioVista’s Artificial Intelligence Platform Boosts Drug Discovery BioVista has eight ongoing projects that involve using its technology to provide discovery, repositioning, adverse event profiling, patient stratification and other services for partners…BioVista said partnering discussions are ongoing for BVA-201 and BVA-601, but the company has not yet determined how far into preclinical and possibly clinical studies … Read More